Skip to main content
SpringerLink
Log in

Precision Medicine in Diabetes

  • Chapter
  • First Online:
Precision Medicine

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 280))

Abstract

Tailoring treatment or management to groups of individuals based on specific clinical, molecular, and genomic features is the concept of precision medicine. Diabetes is highly heterogenous with respect to clinical manifestations, disease progression, development of complications, and drug response. The current practice for drug treatment is largely based on evidence from clinical trials that report average effects. However, around half of patients with type 2 diabetes do not achieve glycaemic targets despite having a high level of adherence and there are substantial differences in the incidence of adverse outcomes. Therefore, there is a need to identify predictive markers that can inform differential drug responses at the point of prescribing. Recent advances in molecular genetics and increased availability of real-world and randomised trial data have started to increase our understanding of disease heterogeneity and its impact on potential treatments for specific groups. Leveraging information from simple clinical features (age, sex, BMI, ethnicity, and co-prescribed medications) and genomic markers has a potential to identify sub-groups who are likely to benefit from a given drug with minimal adverse effects. In this chapter, we will discuss the state of current evidence in the discovery of clinical and genetic markers that have the potential to optimise drug treatment in type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amoah AG, Owusu SK, Schuster DP, Osei K (2002) Pathogenic mechanism of type 2 diabetes in Ghanaians – the importance of beta cell secretion, insulin sensitivity and glucose effectiveness. S Afr Med J 92:377–384

    PubMed  Google Scholar 

  • Anjana RM, Baskar V, Nair ATN, Jebarani S, Siddiqui MK, Pradeepa R, Unnikrishnan R, Palmer C, Pearson E, Mohan V (2020) Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Res Care 8

    Google Scholar 

  • Balaich J, Estrella M, Wu G, Jeffrey PD, Biswas A, Zhao L, Korennykh A, Donia MS (2021) The human microbiome encodes resistance to the antidiabetic drug acarbose. Nature

    Google Scholar 

  • Baye AM, Fanta TG, Siddiqui MK, Dawed AY (2021) The genetics of adverse drug outcomes in type 2 diabetes: a systematic review. Front Genet 12:675053

    CAS  PubMed  PubMed Central  Google Scholar 

  • Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH (2008) Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 83:288–292

    CAS  PubMed  Google Scholar 

  • Bizzotto R, Jennison C, Jones AG, Kurbasic A, Tura A, Kennedy G, Bell JD, Thomas EL, Frost G, Eriksen R, Koivula RW, Brage S, Kaye J, Hattersley AT, Heggie A, McEvoy D, t Hart LM, Beulens JW, Elders P, Musholt PB, Ridderstråle M, Hansen TH, Allin KH, Hansen T, Vestergaard H, Lundgaard AT, Thomsen HS, De Masi F, Tsirigos KD, Brunak S, Viñuela A, Mahajan A, McDonald TJ, Kokkola T, Forgie IM, Giordano GN, Pavo I, Ruetten H, Dermitzakis E, McCarthy MI, Pedersen O, Schwenk JM, Adamski J, Franks PW, Walker M, Pearson ER, Mari A (2021) Processes underlying glycemic deterioration in type 2 diabetes: an IMI DIRECT study. Diabetes Care 44:511–518

    CAS  PubMed  Google Scholar 

  • Bryrup T, Thomsen CW, Kern T, Allin KH, Brandslund I, Jørgensen NR, Vestergaard H, Hansen T, Hansen TH, Pedersen O, Nielsen T (2019) Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 62:1024–1035

    CAS  PubMed  PubMed Central  Google Scholar 

  • Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA, Davies MJ (2020a) 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 63:221–228

    PubMed  Google Scholar 

  • Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA, Davies MJ (2020b) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:487–493

    CAS  PubMed  Google Scholar 

  • Campbell JA, Walker RJ, Smalls BL, Egede LE (2012) Glucose control in diabetes: the impact of racial differences on monitoring and outcomes. Endocrine 42:471–482

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ceriello A, Prattichizzo F, Phillip M, Hirsch IB, Mathieu C, Battelino T (2021) Glycaemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol

    Google Scholar 

  • Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, Hattersley AT (2015) Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 38:1383–1392

    CAS  PubMed  Google Scholar 

  • Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, Wahl S, Elliott HR, Rota F, Scott WR, Zhang W, Tan ST, Campanella G, Chadeau-Hyam M, Yengo L, Richmond RC, Adamowicz-Brice M, Afzal U, Bozaoglu K, Mok ZY, Ng HK, Pattou F, Prokisch H, Rozario MA, Tarantini L, Abbott J, Ala-Korpela M, Albetti B, Ammerpohl O, Bertazzi PA, Blancher C, Caiazzo R, Danesh J, Gaunt TR, de Lusignan S, Gieger C, Illig T, Jha S, Jones S, Jowett J, Kangas AJ, Kasturiratne A, Kato N, Kotea N, Kowlessur S, Pitkäniemi J, Punjabi P, Saleheen D, Schafmayer C, Soininen P, Tai ES, Thorand B, Tuomilehto J, Wickremasinghe AR, Kyrtopoulos SA, Aitman TJ, Herder C, Hampe J, Cauchi S, Relton CL, Froguel P, Soong R, Vineis P, Jarvelin MR, Scott J, Grallert H, Bollati V, Elliott P, McCarthy MI, Kooner JS (2015) Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes Endocrinol 3:526–534

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140

    CAS  PubMed  Google Scholar 

  • Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM (1999) Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 84:2329–2335

    CAS  PubMed  Google Scholar 

  • Chanfreau-Coffinier C, Hull LE, Lynch JA, DuVall SL, Damrauer SM, Cunningham FE, Voight BF, Matheny ME, Oslin DW, Icardi MS, Tuteja S (2019) Projected prevalence of actionable Pharmacogenetic variants and level a drugs prescribed among US veterans health administration pharmacy users. JAMA Netw Open 2:e195345

    PubMed  PubMed Central  Google Scholar 

  • Chen L, Li JH, Kaur V, Muhammad A, Fernandez M, Hudson MS, Goldfine AB, Florez JC (2020) The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. Diabet Med 37:2124–2130

    CAS  PubMed  Google Scholar 

  • Chung WK, Erion K, Florez JC, Hattersley AT, Hivert MF, Lee CG, McCarthy MI, Nolan JJ, Norris JM, Pearson ER, Philipson L, McElvaine AT, Cefalu WT, Rich SS, Franks PW (2020) Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43:1617–1635

    CAS  PubMed  PubMed Central  Google Scholar 

  • Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41:2669–2701

    PubMed  PubMed Central  Google Scholar 

  • Dawed AY, Donnelly L, Tavendale R, Carr F, Leese G, Palmer CN, Pearson ER, Zhou K (2016a) CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes. Diabetes Care 39:1902–1908

    CAS  PubMed  Google Scholar 

  • Dawed AY, Zhou K, Pearson ER (2016b) Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmgenomics Pers Med 9:17–29

    PubMed  PubMed Central  Google Scholar 

  • Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, Elders PJM, Rauh SP, Jones AG, Holl RW, Stingl JC, Franks PW, McCarthy MI, t Hart LM, Pearson ER (2019) Variation in the plasma membrane monoamine transporter (PMAT) (encoded by SLC29A4) and organic cation transporter 1 (OCT1) (encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI DIRECT study. Diabetes Care 42:1027–1033

    CAS  PubMed  Google Scholar 

  • Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, t Hart LM, Giacomini KM, Pearson ER (2021) Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas. Diabetes Care

    Google Scholar 

  • de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM, Escobar JS (2017) Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40:54–62

    PubMed  Google Scholar 

  • Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT (2018a) Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care 41:1844–1853

    PubMed  Google Scholar 

  • Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG (2018b) Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care 41:705–712

    CAS  PubMed  Google Scholar 

  • Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7:442–451

    PubMed  PubMed Central  Google Scholar 

  • Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM, o. b. o. t. M. Consortium (2021) Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data. medRxiv:2021.11.11.21265959

    Google Scholar 

  • Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER (2015) Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64:1786–1793

    CAS  PubMed  Google Scholar 

  • Dujic T, Causevic A, Bego T, Malenica M, Velija-Asimi Z, Pearson ER, Semiz S (2016a) Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes. Diabet Med 33:511–514

    CAS  PubMed  Google Scholar 

  • Dujic T, Zhou K, Tavendale R, Palmer CN, Pearson ER (2016b) Effect of serotonin transporter 5-HTTLPR polymorphism on gastrointestinal intolerance to metformin: a GoDARTS study. Diabetes Care 39:1896–1901

    CAS  PubMed  Google Scholar 

  • Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimčáková L, Pirags V, Kooy A, Brøsen K, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer C, t Hart LM, Giacomini KM, Pearson ER (2017) Variants in pharmacokinetic transporters and glycemic response to metformin: a Metgen meta-analysis. Clin Pharmacol Ther 101:763–772

    CAS  PubMed  PubMed Central  Google Scholar 

  • Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, Khatana SAM, Dayoub EJ, Fanaroff AC, Giri J, Groeneveld PW, Adusumalli S (2021) Association of Race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open 4:e216139

    PubMed  PubMed Central  Google Scholar 

  • Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, Mauldin PD (2011) Regional, geographic, and racial/ethnic variation in glycemic control in a national sample of veterans with diabetes. Diabetes Care 34:938–943

    PubMed  PubMed Central  Google Scholar 

  • Fedotkina O, Sulaieva O, Ozgumus T, Cherviakova L, Khalimon N, Svietleisha T, Buldenko T, Ahlqvist E, Asplund O, Groop L, Nilsson PM, Lyssenko V (2021) Novel reclassification of adult diabetes is useful to distinguish stages of β-cell function linked to the risk of vascular complications: the DOLCE study from northern Ukraine. Front Genet 12:637945

    CAS  PubMed  PubMed Central  Google Scholar 

  • Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262–266

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393

    PubMed  Google Scholar 

  • Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21

    Google Scholar 

  • Gan S, Dawed AY, Donnelly LA, Nair ATN, Palmer CNA, Mohan V, Pearson ER (2020) Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 43:1948–1957

    CAS  PubMed  PubMed Central  Google Scholar 

  • García-Calzón S, Perfilyev A, Martinell M, Ustinova M, Kalamajski S, Franks PW, Bacos K, Elbere I, Pihlajamäki J, Volkov P, Vaag A, Groop L, Maziarz M, Klovins J, Ahlqvist E, Ling C (2020) Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes. Sci Transl Med 12

    Google Scholar 

  • Gill GV, Tekle A, Reja A, Wile D, English PJ, Diver M, Williams AJ, Tesfaye S (2011) Immunological and C-peptide studies of patients with diabetes in northern Ethiopia: existence of an unusual subgroup possibly related to malnutrition. Diabetologia 54:51–57

    CAS  PubMed  Google Scholar 

  • Hall LM, Moran CN, Milne GR, Wilson J, MacFarlane NG, Forouhi NG, Hariharan N, Salt IP, Sattar N, Gill JM (2010) Fat oxidation, fitness and skeletal muscle expression of oxidative/lipid metabolism genes in South Asians: implications for insulin resistance? PLoS One 5:e14197

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hara K, Shojima N, Hosoe J, Kadowaki T (2014) Genetic architecture of type 2 diabetes. Biochem Biophys Res Commun 452:213–220

    CAS  PubMed  Google Scholar 

  • Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

    CAS  PubMed  Google Scholar 

  • Holstein A, Beil W, Kovacs P (2012) CYP2C metabolism of oral antidiabetic drugs – impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol 8:1549–1563

    CAS  PubMed  Google Scholar 

  • IDF (2021) Diabetes Atlas. 9th edn. [ebook] International Diabetes Federation. Available at: https://diabetesatlas.org/. Accessed 29 Nov 2021

  • Jackson AS, Ellis KJ, McFarlin BK, Sailors MH, Bray MS (2009) Body mass index bias in defining obesity of diverse young adults: the training intervention and genetics of exercise response (TIGER) study. Br J Nutr 102:1084–1090

    CAS  PubMed  PubMed Central  Google Scholar 

  • Joffe BI, Panz VR, Wing JR, Raal FJ, Seftel HC (1992) Pathogenesis of non-insulin-dependent diabetes mellitus in the black population of southern Africa. Lancet 340:460–462

    CAS  PubMed  Google Scholar 

  • Kibirige D, Lumu W, Jones AG, Smeeth L, Hattersley AT, Nyirenda MJ (2019) Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clin Diabetes Endocrinol 5:2

    PubMed  PubMed Central  Google Scholar 

  • Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25–33

    CAS  PubMed  Google Scholar 

  • Läll K, Mägi R, Morris A, Metspalu A, Fischer K (2017) Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores. Genet Med 19:322–329

    PubMed  Google Scholar 

  • Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL (2018) Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. Health Aff (Millwood) 37:780–785

    PubMed  Google Scholar 

  • Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, Song X, Ren Y, Shan PF (2020) Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 10:14790

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Walavalkar NM, Dozmorov MG, Rich SS, Civelek M, Guertin MJ (2017) Identification of breast cancer associated variants that modulate transcription factor binding. PLoS Genet 13:e1006761

    PubMed  PubMed Central  Google Scholar 

  • Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup N, Cook JP, Schmidt EM, Wuttke M, Sarnowski C, Mägi R, Nano J, Gieger C, Trompet S, Lecoeur C, Preuss MH, Prins BP, Guo X, Bielak LF, Below JE, Bowden DW, Chambers JC, Kim YJ, Ng MCY, Petty LE, Sim X, Zhang W, Bennett AJ, Bork-Jensen J, Brummett CM, Canouil M, Ec Kardt KU, Fischer K, Kardia SLR, Kronenberg F, Läll K, Liu CT, Locke AE, Luan J, Ntalla I, Nylander V, Schönherr S, Schurmann C, Yengo L, Bottinger EP, Brandslund I, Christensen C, Dedoussis G, Florez JC, Ford I, Franco OH, Frayling TM, Giedraitis V, Hackinger S, Hattersley AT, Herder C, Ikram MA, Ingelsson M, Jørgensen ME, Jørgensen T, Kriebel J, Kuusisto J, Ligthart S, Lindgren CM, Linneberg A, Lyssenko V, Mamakou V, Meitinger T, Mohlke KL, Morris AD, Nadkarni G, Pankow JS, Peters A, Sattar N, Stančáková A, Strauch K, Taylor KD, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tuomilehto J, Witte DR, Dupuis J, Peyser PA, Zeggini E, Loos RJF, Froguel P, Ingelsson E, Lind L, Groop L, Laakso M, Collins FS, Jukema JW, Palmer CNA, Grallert H, Metspalu A et al (2018a) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50:1505–1513

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, Gan W, Kitajima H, Taliun D, Rayner NW, Guo X, Lu Y, Li M, Jensen RA, Hu Y, Huo S, Lohman KK, Zhang W, Cook JP, Prins BP, Flannick J, Grarup N, Trubetskoy VV, Kravic J, Kim YJ, Rybin DV, Yaghootkar H, Müller-Nurasyid M, Meidtner K, Li-Gao R, Varga TV, Marten J, Li J, Smith AV, An P, Ligthart S, Gustafsson S, Malerba G, Demirkan A, Tajes JF, Steinthorsdottir V, Wuttke M, Lecoeur C, Preuss M, Bielak LF, Graff M, Highland HM, Justice AE, Liu DJ, Marouli E, Peloso GM, Warren HR, Afaq S, Afzal S, Ahlqvist E, Almgren P, Amin N, Bang LB, Bertoni AG, Bombieri C, Bork-Jensen J, Brandslund I, Brody JA, Burtt NP, Canouil M, Chen YI, Cho YS, Christensen C, Eastwood SV, Eckardt KU, Fischer K, Gambaro G, Giedraitis V, Grove ML, de Haan HG, Hackinger S, Hai Y, Han S, Tybjærg-Hansen A, Hivert MF, Isomaa B, Jäger S, Jørgensen ME, Jørgensen T, Käräjämäki A, Kim BJ, Kim SS, Koistinen HA, Kovacs P, Kriebel J, Kronenberg F, Läll K, Lange LA, Lee JJ, Lehne B, Li H, Lin KH, Linneberg A, Liu CT, Liu J et al (2018b) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet 50:559–571

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mansour Aly D, Dwivedi OP, Prasad RB, Käräjämäki A, Hjort R, Thangam M, Åkerlund M, Mahajan A, Udler MS, Florez JC, McCarthy MI, Brosnan J, Melander O, Carlsson S, Hansson O, Tuomi T, Groop L, Ahlqvist E (2021) Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes. Nat Genet 53:1534–1542

    CAS  PubMed  Google Scholar 

  • Mathur R, Farmer RE, Eastwood SV, Chaturvedi N, Douglas I, Smeeth L (2020) Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990-2017: a cohort study. PLoS Med 17:e1003106

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mbanya JC, Motala AA, Sobngwi E, Assah FK, Enoru ST (2010) Diabetes in sub-Saharan Africa. Lancet 375:2254–2266

    PubMed  Google Scholar 

  • McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60:793–799

    PubMed  PubMed Central  Google Scholar 

  • McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59:426–435

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mukhopadhyay B, Forouhi NG, Fisher BM, Kesson CM, Sattar N (2006) A comparison of glycaemic and metabolic control over time among South Asian and European patients with type 2 diabetes: results from follow-up in a routine diabetes clinic. Diabet Med 23:94–98

    CAS  PubMed  Google Scholar 

  • Murphy R, Ellard S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4:200–213

    CAS  PubMed  Google Scholar 

  • Oli JM, Adeyemo AA, Okafor GO, Ofoegbu EN, Onyenekwe B, Chukwuka CJ, Onwasigwe CN, Ufelle S, Chen G, Rotimi CN (2009) Basal insulin resistance and secretion in Nigerians with type 2 diabetes mellitus. Metab Syndr Relat Disord 7:595–599

    CAS  PubMed  Google Scholar 

  • Parchman ML, Wang CP (2012) Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c. Prim Care Diabetes 6:19–25

    PubMed  Google Scholar 

  • Pearson ER (2019) Diabetes: is there a future for pharmacogenomics guided treatment? Clin Pharmacol Ther 106:329–337

    PubMed  PubMed Central  Google Scholar 

  • Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281

    CAS  PubMed  Google Scholar 

  • Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477

    CAS  PubMed  Google Scholar 

  • Pilla SJ, Yeh HC, Juraschek SP, Clark JM, Maruthur NM (2018) Predictors of insulin initiation in patients with type 2 diabetes: An analysis of the look AHEAD randomized trial. J Gen Intern Med 33:839–846

    PubMed  PubMed Central  Google Scholar 

  • Ramamoorthy A, Pacanowski MA, Bull J, Zhang L (2015) Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 97:263–273

    CAS  PubMed  Google Scholar 

  • Raymond NT, Paul O’Hare J, Bellary S, Kumar S, Jones A, Barnett AH (2011) Comparative risk of microalbuminuria and proteinuria in UK residents of south Asian and white European ethnic background with type 2 diabetes: a report from UKADS. Curr Med Res Opin 27(Suppl 3):47–55

    CAS  PubMed  Google Scholar 

  • Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585

    CAS  PubMed  PubMed Central  Google Scholar 

  • Riddle MC, Philipson LH, Rich SS, Carlsson A, Franks PW, Greeley SAW, Nolan JJ, Pearson ER, Zeitler PS, Hattersley AT (2020) Monogenic diabetes: from genetic insights to population-based precision in care. Reflections from a diabetes care Editors' expert forum. Diabetes Care 43:3117–3128

    PubMed  PubMed Central  Google Scholar 

  • Roden M, Shulman GI (2019) The integrative biology of type 2 diabetes. Nature 576:51–60

    CAS  PubMed  Google Scholar 

  • Rusu V, Hoch E, Mercader JM, Tenen DE, Gymrek M, Hartigan CR, DeRan M, von Grotthuss M, Fontanillas P, Spooner A, Guzman G, Deik AA, Pierce KA, Dennis C, Clish CB, Carr SA, Wagner BK, Schenone M, Ng MCY, Chen BH, Centeno-Cruz F, Zerrweck C, Orozco L, Altshuler DM, Schreiber SL, Florez JC, Jacobs SBR, Lander ES (2017) Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms. Cell 170:199–212.e20

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shah RR, Gaedigk A (2018) Precision medicine: does ethnicity information complement genotype-based prescribing decisions? Ther Adv Drug Saf 9:45–62

    PubMed  Google Scholar 

  • Siddiqui MK, Anjana R, Dawed AY, Martoeau C, Srinivasan S, Saravanan J, Madanagopal SK, Veluchamy A, Pradeepa R, Sattar N, Venkatesan R, Palmer CNA, Pearson ER, Mohan V (2021) Young onset diabetes in Asian Indians is associated with lower measured and genetically determined beta-cell function: an INSPIRED study. medRxiv:2021.09.07.21263208

    Google Scholar 

  • Singh S, Willers I, Held K, Goedde W (1989) Lesch-Nyhan syndrome and HPRT variants: study of heterogeneity at the gene level. Adv Exp Med Biol 253a:145–150

    CAS  PubMed  Google Scholar 

  • Slieker RC, Donnelly LA, Fitipaldi H, Bouland GA, Giordano GN, Åkerlund M, Gerl MJ, Ahlqvist E, Ali A, Dragan I, Elders P, Festa A, Hansen MK, van der Heijden AA, Mansour Aly D, Kim M, Kuznetsov D, Mehl F, Klose C, Simons K, Pavo I, Pullen TJ, Suvitaival T, Wretlind A, Rossing P, Lyssenko V, Legido Quigley C, Groop L, Thorens B, Franks PW, Ibberson M, Rutter GA, Beulens JWJ, t Hart LM, Pearson ER (2021a) Distinct molecular signatures of clinical clusters in people with type 2 diabetes: an IMI-RHAPSODY study. Diabetes 70:2683–2693

    CAS  PubMed  PubMed Central  Google Scholar 

  • Slieker RC, Donnelly LA, Fitipaldi H, Bouland GA, Giordano GN, Åkerlund M, Gerl MJ, Ahlqvist E, Ali A, Dragan I, Festa A, Hansen MK, Mansour Aly D, Kim M, Kuznetsov D, Mehl F, Klose C, Simons K, Pavo I, Pullen TJ, Suvitaival T, Wretlind A, Rossing P, Lyssenko V, Legido-Quigley C, Groop L, Thorens B, Franks PW, Ibberson M, Rutter GA, Beulens JWJ, t Hart LM, Pearson ER (2021b) Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia 64:1982–1989

    CAS  PubMed  PubMed Central  Google Scholar 

  • Spence JD, Rayner BL (2018) Hypertension in blacks: individualized therapy based on renin/aldosterone phenotyping. Hypertension 72:263–269

    CAS  PubMed  Google Scholar 

  • Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 36:2271–2279

    PubMed  PubMed Central  Google Scholar 

  • Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 72:148–154

    CAS  PubMed  Google Scholar 

  • Thakarakkattil Narayanan Nair A, Donnelly LA, Dawed AY, Gan S, Anjana RM, Viswanathan M, Palmer CNA, Pearson ER (2020) The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus. Endocrinol Diabetes Metab 3:e00108

    PubMed  PubMed Central  Google Scholar 

  • Thomsen SK, Raimondo A, Hastoy B, Sengupta S, Dai XQ, Bautista A, Censin J, Payne AJ, Umapathysivam MM, Spigelman AF, Barrett A, Groves CJ, Beer NL, Manning Fox JE, McCarthy MI, Clark A, Mahajan A, Rorsman P, MacDonald PE, Gloyn AL (2018) Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic β-cells. Nat Genet 50:1122–1131

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tillin T, Hughes AD, Godsland IF, Whincup P, Forouhi NG, Welsh P, Sattar N, McKeigue PM, Chaturvedi N (2013) Insulin resistance and truncal obesity as important determinants of the greater incidence of diabetes in Indian Asians and African Caribbeans compared with Europeans: the Southall and Brent REvisited (SABRE) cohort. Diabetes Care 36:383–393

    PubMed  PubMed Central  Google Scholar 

  • Udler MS, Kim J, von Grotthuss M, Bonàs-Guarch S, Cole JB, Chiou J, Boehnke M, Laakso M, Atzmon G, Glaser B, Mercader JM, Gaulton K, Flannick J, Getz G, Florez JC (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med 15:e1002654

    PubMed  PubMed Central  Google Scholar 

  • Ustinova M, Ansone L, Silamikelis I, Rovite V, Elbere I, Silamikele L, Kalnina I, Fridmanis D, Sokolovska J, Konrade I, Pirags V, Klovins J (2020) Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response. PLoS One 15:e0237400

    CAS  PubMed  PubMed Central  Google Scholar 

  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71:1269–1324

    CAS  PubMed  Google Scholar 

  • Whyte MB, Hinton W, McGovern A, van Vlymen J, Ferreira F, Calderara S, Mount J, Munro N, de Lusignan S (2019) Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis. PLoS Med 16:e1002942

    PubMed  PubMed Central  Google Scholar 

  • Williams LK, Padhukasahasram B, Ahmedani BK, Peterson EL, Wells KE, González Burchard E, Lanfear DE (2014) Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99:3160–3168

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wright AK, Welsh P, Gill JMR, Kontopantelis E, Emsley R, Buchan I, Ashcroft DM, Rutter MK, Sattar N (2020) Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. Diabetologia 63:1542–1553

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F (2017a) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858

    CAS  PubMed  Google Scholar 

  • Wu Y, Jing R, Dong Y, Kuang Q, Li Y, Huang Z, Gan W, Xue Y, Li Y, Li M (2017b) Functional annotation of sixty-five type-2 diabetes risk SNPs and its application in risk prediction. Sci Rep 7:43709

    PubMed  PubMed Central  Google Scholar 

  • Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, Ahmed MS (2009) Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol 78:1483–1490

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58:1434–1439

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, Palmer CN, Pearson ER (2010) Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 87:52–56

    CAS  PubMed  Google Scholar 

  • Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CN, Donnelly P, Pearson ER (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117–120

    CAS  PubMed  Google Scholar 

  • Zhou K, Donnelly L, Yang J, Li M, Deshmukh H, Van Zuydam N, Ahlqvist E, Spencer CC, Groop L, Morris AD, Colhoun HM, Sham PC, McCarthy MI, Palmer CN, Pearson ER (2014a) Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2:481–487

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou K, Donnelly LA, Morris AD, Franks PW, Jennison C, Palmer CN, Pearson ER (2014b) Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study. Diabetes Care 37:718–724

    CAS  PubMed  Google Scholar 

  • Zhou K, Pedersen HK, Dawed AY, Pearson ER (2016a) Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol 12:337–346

    CAS  PubMed  Google Scholar 

  • Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, t Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER (2016b) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055–1059

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zou X, Zhou X, Zhu Z, Ji L (2019) Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol 7:9–11

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK

    Adem Y. Dawed, Eram Haider & Ewan R. Pearson

Authors
  1. Adem Y. Dawed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eram Haider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewan R. Pearson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ewan R. Pearson .

Editor information

Editors and Affiliations

  1. Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany

    Ingolf Cascorbi

  2. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

    Matthias Schwab

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dawed, A.Y., Haider, E., Pearson, E.R. (2022). Precision Medicine in Diabetes. In: Cascorbi, I., Schwab, M. (eds) Precision Medicine. Handbook of Experimental Pharmacology, vol 280. Springer, Cham. https://doi.org/10.1007/164_2022_590

Download citation

Publish with us

Policies and ethics

Search

Navigation